Seismic Therapeutic Launches With $101 Million Series A Financing To Usher In A New Era Of Immunology Drug Development Integrating Machine Learning
Seismic Therapeutic Launches With $101 Million Series A Financing To Usher In A New Era Of Immunology Drug Development Integrating Machine Learning
02/09/22, 12:00 PM
Location
watertownMoney raised
$101 million
Round Type
series a
Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced its launch and financing of $101 million. The Series A was led by Lightspeed Venture Partners with participation from lead founding investors Timothy A. Springer and Polaris Partners, along with new investors GV, Boxer Capital, Samsara BioCapital, and management and founders. Seismic’s IMPACTTM platform systematically integrates machine learning, structural biology, protein engineering and translational immunology to invent novel biologics and optimize properties with significantly improved efficiency and scale over conventional therapeutics discovery
Company Info
Location
watertown, south dakota, united states
Additional Info
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow up on Twitter @Seismic_Tx and on LinkedIn.